• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cerebral Therapeutics raises $3m for epilepsy drug-device therapy

June 21, 2018 By Sarah Faulkner

Cerebral TherapeuticsCerebral Therapeutics closed a $3 million Series A financing round this week to support the development of its drug-device therapy designed for patients with refractory epilepsy.

The Aurora, Co.-based company’s product uses an implanted, refillable catheter system to deliver a continuous, intracerebroventricular dose of an anti-epileptic drug – valproic acid.

Investors that contributed to Cerebral Therapeutics’ Series A round included Granite Point Capital Management and Vivo Capital. The company is slated to use its newly-acquired funds to support an investigational new drug application to the FDA.

“I am excited about the significant capability our new investors and board members bring to Cerebral Therapeutics,” CEO Dr. Dan Abrams said in prepared remarks. “We believe we are now well positioned to advance our potentially life-changing therapy for adult patients with refractory epilepsy while establishing a strong foundation for future therapeutic opportunities in other uncontrolled neurological conditions.”

In connection with the funding round, Warren Lammert, founder & chief investment officer of Granite Point Capital; Mahendra Shah, managing director at Vivo Capital; and Stephen Farr, co-founder, president & CEO of Zogenix have joined Cerebral Therapeutics’ board.

Dr. Andre Cheng, portfolio manager at Granite Point Capital, will join as a board observer, according to Cerebral Therapeutics.

“Chronic drug delivery directly to the brain is an innovative approach that offers hope to people living with uncontrolled seizures and to those living with other serious neurological disorders,” Lammert said.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Neurological, Pharmaceuticals Tagged With: Cerebral Therapeutics

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS